1887
Volume 2022 Number 1
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Coronavirus Disease 2019 (COVID-19) was first discovered in China and resulted in a pandemic crisis.1,2 Many agents were investigated with inconclusive outcomes.3 This study was conducted to compare the efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in the treatment of patients with COVID-19. This retrospective, multicenter, observational study was conducted on adult patients hospitalized in COVID-19 facilities in Qatar. Patients were included if they had pneumonia and received darunavir-cobicistat or lopinavir-ritonavir for at least three days as part of their COVID-19 treatment. Data were collected from patients’ electronic medical records. The primary outcome was a composite endpoint of time to clinical improvement and/or virological clearance. Data were analyzed descriptively and inferential statistics were applied at alpha level of 0.05. A total of 400 patients’ medical records were analyzed, of whom 100 received darunavir-cobicistat and 300 received lopinavir-ritonavir. The majority of patients were male (92.5%), with a mean (SD) time from symptoms onset to start of therapy of 7.57 days (SD 4.89). Patients who received lopinavir-ritonavir had a significantly faster time to the primary composite endpoint of clinical improvement and/or virological clearance than patients who received darunavir-cobicistat (4 days [IQR 3-7] vs. 6.5 days [IQR 4-12]; HR 1.345 [95%CI: 1.070–1.691], p = 0.011) [Figure 1]. Patients who received lopinavir-ritonavir had a significantly faster time to clinical improvement (5 days [IQR 3-8] vs. 8 days [IQR 4-13]; HR 1.520 (95%CI: 1.2–1.925), p = 0.000), and slower time to virological clearance than those who received darunavir-cobicistat (25 days [IQR 15-33] vs. 21 days [IQR 12.8-30]; HR 0.772 (95%CI: 0.607-0.982), p = 0.035) [Figure 2]. No significant difference in adverse events incidence or severity was observed. In patients with COVID-19, early treatment with lopinavir-ritonavir was associated with faster time to reach the primary composite endpoint of clinical improvement and/or virological clearance than treatment with darunavir-cobicistat. Future trials are warranted to confirm these findings.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.qhc.9
2021-11-30
2022-05-17
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/1/jemtac.2022.qhc.9.html?itemId=/content/journals/10.5339/jemtac.2022.qhc.9&mimeType=html&fmt=ahah

References

  1. Chauhan S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed J.2020; 43:(4):334-340. doi:10.1016/j.bj.2020.05.023.
    [Google Scholar]
  2. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents [Internet]. 2020 Mar; 55:(3):105924. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857920300674.
    [Google Scholar]
  3. World Health Organization. Landscape analysis of therapeutics as 21st March 2020 [Internet]. 2020 [cited 2021 Jan 20]. p. 1–49. Available from: https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.qhc.9
Loading
/content/journals/10.5339/jemtac.2022.qhc.9
Loading

Data & Media loading...

  • Article Type: Conference Abstract
Keyword(s): Antiviral TherapyCoronavirusCOVID-19Darunavir-Cobicistat and Lopinavir-Ritonavir
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error